174 related articles for article (PubMed ID: 22342644)
1. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.
Rahman MA; Amin AR; Wang X; Zuckerman JE; Choi CH; Zhou B; Wang D; Nannapaneni S; Koenig L; Chen Z; Chen ZG; Yen Y; Davis ME; Shin DM
J Control Release; 2012 May; 159(3):384-92. PubMed ID: 22342644
[TBL] [Abstract][Full Text] [Related]
2. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
Rahman MA; Amin AR; Wang D; Koenig L; Nannapaneni S; Chen Z; Wang Z; Sica G; Deng X; Chen ZG; Shin DM
Clin Cancer Res; 2013 Jul; 19(13):3416-28. PubMed ID: 23719266
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
[TBL] [Abstract][Full Text] [Related]
4. SiRNA-Mediated
Xue T; Wang L; Li Y; Song H; Chu H; Yang H; Guo A; Jiao J
Int J Med Sci; 2019; 16(11):1510-1516. PubMed ID: 31673243
[No Abstract] [Full Text] [Related]
5. Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Iwamoto K; Nakashiro K; Tanaka H; Tokuzen N; Hamakawa H
Int J Oncol; 2015 May; 46(5):1971-7. PubMed ID: 25738429
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer.
Chen WH; Lecaros RL; Tseng YC; Huang L; Hsu YC
Cancer Lett; 2015 Apr; 359(1):65-74. PubMed ID: 25596376
[TBL] [Abstract][Full Text] [Related]
7. Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Xu L; Yeudall WA; Yang H
Acta Biomater; 2017 Jul; 57():251-261. PubMed ID: 28438704
[TBL] [Abstract][Full Text] [Related]
8. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
Davis ME; Zuckerman JE; Choi CH; Seligson D; Tolcher A; Alabi CA; Yen Y; Heidel JD; Ribas A
Nature; 2010 Apr; 464(7291):1067-70. PubMed ID: 20305636
[TBL] [Abstract][Full Text] [Related]
9. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.
Heidel JD; Liu JY; Yen Y; Zhou B; Heale BS; Rossi JJ; Bartlett DW; Davis ME
Clin Cancer Res; 2007 Apr; 13(7):2207-15. PubMed ID: 17404105
[TBL] [Abstract][Full Text] [Related]
10. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
Zhang M; Wang J; Yao R; Wang L
Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
[TBL] [Abstract][Full Text] [Related]
11. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
12. Cancer Fighting SiRNA-RRM2 Loaded Nanorobots.
Sharma A; Kumar P; Ambasta RK
Pharm Nanotechnol; 2020; 8(2):79-90. PubMed ID: 32003677
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P
Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884
[TBL] [Abstract][Full Text] [Related]
14. Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells.
Lo WL; Chien Y; Chiou GY; Tseng LM; Hsu HS; Chang YL; Lu KH; Chien CS; Wang ML; Chen YW; Huang PI; Hu FW; Yu CC; Chu PY; Chiou SH
Biomaterials; 2012 May; 33(14):3693-709. PubMed ID: 22361100
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
17. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
18. Targeting HOTAIR Induces Mitochondria Related Apoptosis and Inhibits Tumor Growth in Head and Neck Squamous Cell Carcinoma in vitro and in vivo.
Kong L; Zhou X; Wu Y; Wang Y; Chen L; Li P; Liu S; Sun S; Ren Y; Mei M; Wang X; Zhang L
Curr Mol Med; 2015; 15(10):952-60. PubMed ID: 26592246
[TBL] [Abstract][Full Text] [Related]
19. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
20. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
